Login to Your Account

AACR 2013

Epigenetics Now Goes Far Beyond HDAC Inhibitors

By Anette Breindl
Science Editor

Tuesday, April 9, 2013

Several presentations at the American Association for Cancer Research's (AACR) Annual Meeting this week underscored the size of the epigenetic space. Targeting epigenetic alterations has gone far beyond histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors, which are the two classes of epigenetic enzymes that have approved drugs targeting them.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription